The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10, 2024, in San Diego, USA. This global event brought together leading experts in hematology to discuss the latest advancements in the field. At the meeting, the team led by Dr. Ruidong Zhang from Beijing Children’s Hospital，Capital Medical University presented significant findings (Abstract O312) on the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL), providing fresh insights and possibilities for future therapies. Hematology Frontier invited Dr. Peijing Qi, the study's lead investigator, to provide an in-depth analysis of the research and its implications for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego from December 7–10, 2024, brought together global hematology experts to discuss the latest research advancements. Among the noteworthy contributions, Dr. Qingxiao Song’s team from the Hematology Medical Center of The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) had three studies selected (O263, P3391, P4777), with two of them earning ASH Abstract Achievement Awards. These studies offer new insights and therapeutic possibilities for chronic graft-versus-host disease (cGVHD). Hematology Frontier invited Dr. Qingxiao Song for an in-depth analysis of these groundbreaking studies.

The 66th American Society of Hematology (ASH) Annual Meeting concluded successfully from December 7 to 10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts numerous experts and scholars worldwide to discuss groundbreaking research and advancements in hematology.At this year’s ASH meeting, the team led by Dr. Bing Xu and Dr. Zhijuan Lin from The First Affiliated Hospital of Xiamen University presented multiple studies, including one oral presentation. Their research covered various topics such as the immune microenvironment of Epstein-Barr Virus-positive diffuse large B-cell lymphoma (EBV+DLBCL), the prognostic relevance of SUVmax in follicular lymphoma (FL), and immune microenvironmental changes in FL patients with early progression. Hematology Frontier had the privilege of interviewing Professor Zhijuan Lin on-site to discuss her team's findings and the latest significant developments in FL research presented at the conference.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7–10, 2024, in San Diego, USA. As the largest international academic conference in hematology, it showcased cutting-edge research and the latest advancements in drug development, representing the highest level of academic achievement in the field. Severe aplastic anemia (SAA) remains a challenging condition to treat, with a poor prognosis, making it a focal point for research. At this year's ASH meeting, Dr. Fengkui Zhang and his team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented a study (Abstract 304) exploring the efficacy of combining the novel thrombopoietin receptor agonist (TPO-RA), Hetrombopag, with immunosuppressive therapy (IST) for treating SAA. The study demonstrated promising results. In an exclusive interview, Hematology Frontier delved into the findings and implications of this research with Professor Zhang. Below is a detailed summary and analysis of the study and interview.

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights of this year’s conference were seven groundbreaking studies from Dr. Xiaowen Tang’s team at The First Affiliated Hospital of Soochow University. These included two oral presentations (O270, O683) and five poster presentations (P3384, P3493, P4197, P4284, P4836). Covering key areas such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), CAR-T cell therapy, and hematopoietic stem cell transplantation (HSCT), the research showcased the team's innovative contributions to hematology. Hematology Frontier interviewed Professor Tang on-site to explore the clinical significance of the two oral presentations, injecting new vitality into the advancement of hematology.

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights was a poster presentation (P4196) by Dr. Ying Wang from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study explored the efficacy and safety of CD19 CAR-T therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), demonstrating its potential to improve remission and survival rates. Hematology Frontier interviewed Professor Wang to analyze the study's key findings and the future prospects of CD19 CAR-T therapy.